BACKGROUND: Several studies have associated elevated liver enzymes (LFTs), obesity, and type 2 diabetes (T2DM), and a link has been established between insulin resistance (IR) and elevated ferritin concentrations. We examined the relationship between LFTs, ferritin, and IR in morbid obese subjects and the effect of weight loss after bariatric surgery. METHODS: We measured liver enzymes, ferritin, insulin resistance, and glucose tolerance (by OGTT) in 159 morbid obese subjects (BMI = 44.4 +/- 0.4 kg/m(2)) at baseline, 6 months and 1 year after laparoscopic-adjustable-gastric banding (LAGB). Subjects were divided in two groups: increased LFTs (ALT > 30; AST/ALT < 1) vs. normal LFTs. RESULTS: A large proportion of morbid obese subjects had increased LFTs (44%) which were associated with increased IR and ferritin, suggesting potential liver disease. A majority of the morbidly obese with increased LFTs, IGT, and T2DM, were male and had almost double ferritin concentrations, strongly correlated with ALT (r = 0.43, p < 0.0001). Both ferritin and ALT correlated with waist circumference and IR. One year after, LAGB glucose tolerance improved, LFTs and IR were reduced; ferritin did not change significantly, but was still correlated with IR. CONCLUSIONS: Ferritin may be an additional useful marker for more severe hepatic IR.
BACKGROUND: Several studies have associated elevated liver enzymes (LFTs), obesity, and type 2 diabetes (T2DM), and a link has been established between insulin resistance (IR) and elevated ferritin concentrations. We examined the relationship between LFTs, ferritin, and IR in morbid obese subjects and the effect of weight loss after bariatric surgery. METHODS: We measured liver enzymes, ferritin, insulin resistance, and glucose tolerance (by OGTT) in 159 morbid obese subjects (BMI = 44.4 +/- 0.4 kg/m(2)) at baseline, 6 months and 1 year after laparoscopic-adjustable-gastric banding (LAGB). Subjects were divided in two groups: increased LFTs (ALT > 30; AST/ALT < 1) vs. normal LFTs. RESULTS: A large proportion of morbid obese subjects had increased LFTs (44%) which were associated with increased IR and ferritin, suggesting potential liver disease. A majority of the morbidly obese with increased LFTs, IGT, and T2DM, were male and had almost double ferritin concentrations, strongly correlated with ALT (r = 0.43, p < 0.0001). Both ferritin and ALT correlated with waist circumference and IR. One year after, LAGB glucose tolerance improved, LFTs and IR were reduced; ferritin did not change significantly, but was still correlated with IR. CONCLUSIONS: Ferritin may be an additional useful marker for more severe hepatic IR.
Authors: Michael Haap; Andreas Fritsche; Heinz Joachim Mensing; Hans-Ulrich Häring; Michael Stumvoll Journal: Ann Intern Med Date: 2003-11-18 Impact factor: 25.391
Authors: R K Schindhelm; J M Dekker; G Nijpels; C D A Stehouwer; L M Bouter; R J Heine; M Diamant Journal: Diabet Med Date: 2007-04 Impact factor: 4.359
Authors: Istvan S Vari; Beverley Balkau; Adrian Kettaneh; Philippe André; Jean Tichet; Frédéric Fumeron; Emile Caces; Michel Marre; Bernard Grandchamp; Pierre Ducimetière Journal: Diabetes Care Date: 2007-04-06 Impact factor: 19.112
Authors: N G Forouhi; A H Harding; M Allison; M S Sandhu; A Welch; R Luben; S Bingham; K T Khaw; N J Wareham Journal: Diabetologia Date: 2007-03-02 Impact factor: 10.122
Authors: Kristina M Utzschneider; Anna Largajolli; Alessandra Bertoldo; Santica Marcovina; James E Nelson; Matthew M Yeh; Kris V Kowdley; Steven E Kahn Journal: J Diabetes Complications Date: 2013-11-26 Impact factor: 2.852
Authors: Glenn S Gerhard; Ravi Chokshi; Christopher D Still; Peter Benotti; G Craig Wood; Mollie Freedman-Weiss; Cody Rider; Anthony T Petrick Journal: Patient Saf Surg Date: 2011-01-10
Authors: Lars Stechemesser; Sebastian K Eder; Andrej Wagner; Wolfgang Patsch; Alexandra Feldman; Michael Strasser; Simon Auer; David Niederseer; Ursula Huber-Schönauer; Bernhard Paulweber; Stephan Zandanell; Sandra Ruhaltinger; Daniel Weghuber; Elisabeth Haschke-Becher; Christoph Grabmer; Eva Rohde; Christian Datz; Thomas K Felder; Elmar Aigner Journal: Mol Metab Date: 2016-10-31 Impact factor: 7.422